SCHEMBL3448295

SCHEMBL3448295

Fc1ccc(Nc2ncc(-c3cncnc3)c(-n3cnc(Cl)c3Cl)n2)cc1Cl

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.45
STK17A Q9UEE5 2/20 0.41
STK17B O94768 1/20 0.41
GRM4 Q14833 1/20 0.39
AXL P30530 3/20 0.38
APP P05067 2/20 0.38
ULK1 O75385 1/20 0.38
EGFR P00533 4/20 0.37
KDR P35968 1/20 0.37
TDP2 O95551 1/20 0.37
CTSC P53634 1/20 0.37
PDGFRB P09619 1/20 0.36
FGFR1 P11362 1/20 0.36
SRC P12931 1/20 0.36
PDGFRA P16234 1/20 0.36
STAT5A P42229 1/20 0.36
ACVR1 Q04771 1/20 0.36
PKMYT1 Q99640 1/20 0.36
SYK P43405 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3448297 0.90 MAPK1 (0.50) MAPK1STK17ASTK17BAXLAPP
SCHEMBL3377106 0.86 XDH (0.42) MAPK1STK17ASTK17BEGFRKDR
SCHEMBL3447144 0.83 MAPK1 (0.47) MAPK1STK17ASTK17BAXLAPP
SCHEMBL3450615 0.83 MAPK1 (0.46) MAPK1STK17ASTK17BGRM4AXL
SCHEMBL3448245 0.82 MAPK1 (0.47) MAPK1STK17ASTK17BGRM4AXL
SCHEMBL3449347 0.82 MAPK1 (0.47) MAPK1STK17ASTK17BGRM4AXL
SCHEMBL3450301 0.82 MAPK1 (0.43) MAPK1STK17ASTK17BGRM4AXL
SCHEMBL3447505 0.82 MAPK1 (0.49) MAPK1STK17ASTK17BGRM4AXL
SCHEMBL3376192 0.81 FGFR1 (0.42) STK17ASTK17BAXLEGFRFGFR1
SCHEMBL3426298 0.81 MAPK1 (0.48) MAPK1STK17ASTK17BGRM4AXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD MAPK1 2905/4885STK17A 1984/4885STK17B 2457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.